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Abstract
We aimed to investigate the effects of nebivolol and quinapril treatments on P-wave duration 
and dispersion in hypertensive patients. Hypertensive patients who were in sinus rhythm were 
assigned to the two treatment groups and received either 20 mg quinapril/day or 5 mg nebivolol/
day. P-Wave dispersion (PWD) was measured at baseline and after four weeks of treatment and 
defined as the difference between the maximum (Pmax) and the minimum (Pmin) P-wave 
duration. The study group consisted of 54 patients (Mean age: 53 ± 9 years, 46% women) with 
27 patients in each group. At 4-week follow up both treatment groups showed a significant 
reduction (p<0.001) in systolic (SBP) and diastolic blood pressure (DBP). Heart rate (HR) 
reduction was significant in patients receiving nebivolol (P=0.001). Both groups showed a 
similar (P=0.413 for PWD, p=0.651 for Pmax) but significant reduction in PWD (nebivolol: 
-16±14, P<0.0001 and quinapril: -13±11, P<0.0001) and Pmax (nebivolol: -10±11, P=0.001 and 
quinapril: -9±11, P=0.001). A 2 (Time) x 2 (Group) mixed-model repeated-measures analysis of 
variance revealed that the main effect of Time was significant for Pmax (P=0.002) and PWD 
(P=0.008) after controlling for changes in SBP, DBP and HR. However, the main effect of 
Group and Time x Group interaction was not significant for both variables (All p values >0.05). 
In conclusion, short-term treatment with nebivolol and quinapril produces a similar but 
significant reduction in Pmax and PWD in hypertensive patients. This effect is independent of 
blood pressure and heart rate changes.
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Introduction
The surface electrocardiogram (ECG) is the most common non-invasive method used for 
cardiovascular evaluations. Increased P-wave dispersion (PWD) and maximum P-wave duration 
(Pmax) are considered to be the non-invasive indicators of prolonged and heterogeneous atrial 
conduction [1]. Accordingly, increased PWD and Pmax have shown to be useful non-invasive 
tools in prediction of the atrial fibrillation (AF) [1-4]. Hypertensive patients have an increased 
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risk of AF which may be related to impaired homogeneity of atrial conduction [2]. Both 
angiotensin converting enzyme (ACE) inhibitors and beta blockers are widely used drugs for the 
treatment of hypertension. Renin angiotensin system (RAS) blockade by either ACE inhibitors 
or angiotensin II receptor blockers (ARBs) is associated with a reduced risk of AF in patients 
with hypertension or heart failure [5,6]. Beta-blockers reduces incidence of AF in patients with 
heart failure [7]. Nebivolol has a unique chemical structure and pharmacologic profile, which 
combines highly selective β1- adrenergic receptor blockade with vasodilating action [8]. To date 
no study compared effect of beta-blockers and ACE inhibitors on P-wave duration and 
dispersion. Here we aimed to investigate the effect of nebivolol and quinapril on P-wave 
duration and dispersion in newly diagnosed hypertensive patients.                                     
Methods
The study included newly diagnosed hypertensive patients who were in sinus rhythm. Blood 
pressure measurements were done in the morning for the 3 consecutive days with an appropriate 
sized cuff mercury sphygmomanometer (ERKA, Bad Tolz, Germany). The patients were 
allowed to take a rest at least 10 minutes before each blood pressure measurement, without tea 
and coffee intake or smoking at least 30 minutes prior to the measurement. Patients who had a 
blood pressure value of ≥140/90 mm Hg and <180/110 mmHg were included. We applied the 
following exclusion criteria: presence of (1) malignant or secondary hypertension; (2) ischemic 
or valvular heart disease; (3) heart failure; (4) renal dysfunction; (5) sustain atrial or ventricular 
arrhythmias; (6) antiarrhythmic treatment; (7) chronic obstructive lung disease or pulmonary 
hypertension; (8) neurological, oncological or rheumatological disease; (9) pregnancy; (10) a 
body mass index (BMI)  ≥35 kg/m2; (11) technically insufficient echocardiographic images; (12) 
left ventricular ejection fraction (LVEF) < 55%; (12) QRS duration ≥ 120 millisecond (ms); (13) 
unrecognized P-wave in ≥ 3 leads; (14) any  contraindication to beta-blockers or ACE inhibitors. 
Eligible patients were approached for study participation and informed consent was obtained 
from all participants. The recruitment of the patients was completed prospectively in 6 months 
between December 1st, 2005 and May 31st, 2006.                                                                     
Electrocardiograms   were   obtained   using   a   3-channel   standard   12-lead   synchronous 
electrocardiography apparatus (Cardiofax GEM-9020 K, Nihon Kohden, Japan) with a rate of 50 
mm/seconds and amplitude of 10 mV including at least 3 QRS complexes for each derivation. 
During recordings, the patients were allowed to breathe freely, but not to speak. The P-wave 
durations for each derivation was manually analyzed through a x10 magnifying glass. The 
beginning of P-wave was considered as intersection point of isoelectric line with the P-wave 
while the end point was the intersection of isoelectric line with the last point of P-wave. The 
difference between the longest and shortest P-waves was defined as PWD. All measurements 
were done by the same cardiologist  who was blinded  to clinical characteristics  of the 
participants.
A transthoracic echocardiography was performed in all patients using a 3.2 MHz probe (Acuson 
Sequoia 512, Siemens, Germany). Parasternal long- and short-axis, apical four chamber and two 
chamber  views were obtained,  and left ventricular systolic and diastolic functions were 
evaluated. Left atrium diameter, posterior wall thickness (PWT), interventricular septal thickness 
(IVST), left ventricular end-systolic diameter  (LVESD) and left ventricular end-diastolic 
diameter (LVEDD) were measured for each patient. The left ventricular muscle mass (LVM) 
was calculated with the Devereux formula [9]; LVM= 0.8 {1.04(IVST + LVESD  + PWT)3 - 
(LVEDD)3} + 0.6. The LVM index was calculated as LVM divided by body surface area (BSA). 
Left ventricular hypertrophy was considered present when the LVM index was >125g/m2 in 
men,   and   >110g/m2  in   women   [10].                                                                     
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The recruited patients were assigned to the two treatment groups in a sequential order and 
received either 20 mg quinapril/day or 5 mg nebivolol/day treatment. A brochure explaining life 
style changes (i.e. reducing weight and salt intake) was given to all patients. Lipid profile and 
renal function tests were performed for each patient, including the measurement of height and 
weight. BMI was calculated as weight in kilograms divided by height in square meters. The 
patients who had a BMI ≥ 30 kg/m2 were defined as obese. All patients were reevaluated at 4-
weeks   follow   up.   No   other   antihypertensive   drugs   or   any   other   drugs   with   effects   on 
cardiovascular system were allowed during the study period.   The study was conducted in 
accordance   to   the  Helsinki  Declaration   with   the  permission   of  the   local  ethical   board.
Statistical   Analysis                                                                                
Continuous data were expressed as the mean ± standard deviation; categorical data were 
expressed as numbers with percentages. The Shapiro-Wilk test was used to assess the normality 
of the continuous data. Differences in continuous data were analyzed by using the Students' t or 
Mann-Whitney U test in two independent groups. Categorical data were compared by using the 
Chi-square test or Fisher's Exact test in two independent groups. T or Wilcoxon test for paired 
samples was used to assess changes in the variables over time within each group. A 2 (Time) x 2 
(Group) mixed-model repeated-measures analysis of variance (ANOVA) was performed to 
compare between-group differences .Changes in P-wave parameters were adjusted for the 
changes in blood pressure and heart rate in this ANOVA model. A two tailed p value < 0.05 was 
considered statistically significant. All statistical analyses were performed using the SPSS 
(statistical Package for the Social Sciences) statistical software package (Version 12: SPSS Inc, 
Chicago,   IL,   USA).                                                                          
Results
A total of 62 consecutive patients, 31 in each group, were recruited. Two patients who didn't 
comply with the treatment regimen (1 in quinapril group, 1 in nebivolol group), and three 
patients who didn't attend the control visit at week 4 (2 in quinapril group, 1 in nebivolol group) 
and three patients who failed to follow the instructions (1 in quinapril group, 2 in nebivolol 
group) were excluded. Thus, the study group consisted of 54 patients (Mean age: 53 ± 9 years, 
46% women) with 27 patients in each group. The baseline characteristics of the two study 
groups were comparable (Table 1). Mean blood pressure, heart rate, Pmax, minimum P-wave 
duration (Pmin) and PWD changes from baseline to week 4 (delta) in each group are shown in 
Table 2 and Figure. At 4-week follow up both treatment groups showed a significant reduction 
in systolic (SBP) and diastolic blood pressure (DBP). The delta DBP was significantly higher in 
the nebivolol group than in the quinapril group (-13±9 vs. -8±5, p=0.037) but delta SBP was 
similar between groups (-29±11 vs. -24±11, p=0.079, Table 3). Heart rate (HR) reduction was 
significant in the nebivolol treated patients (P=0.001) however, the difference in delta HR was 
not significant between two treatment groups (-7±9 vs. -3±14, P=0.112).
Both groups showed a similar but significant reduction in PWD and Pmax (Table 3). The delta 
PWD was -16±14 ms (P<0.0001) and -13±11ms (P<0.0001) in the nebivolol and quinapril 
group, respectively. Corresponding figure for Pmax was -10±11 ms (P=0.001) and -9±11 ms 
(P=0.001), respectively. The difference in delta PWD and delta Pmax were not statistically 
significant between two groups (P=0.413 and p=0.651, respectively).
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Table 1. Baseline characteristics of the treatment groups
SD represent standard deviation; DM, diabetes mellitus; BMI, body mass index; BSA, body surface area; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; LVEF, left ventricular ejection 
fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; IVRT, 
isovolumic relaxation time; DT, deceleration time; ms, millisecond; mm, millimeter; LVM, left ventricular mass; 
LVH, left ventricular hypertrophy
Table 2. Pre- and post-treatment values of blood pressure, heart rate, P-wave parameters and left 
atrial diameter in the nebivolol and quinapril groups.
Data are expressed as mean ± standard deviation. SBP represent systolic blood pressure; DBP, diastolic blood 
pressure; PMax, maximum P-wave; PMin, minimum P-wave; PWD, P-wave dispersion.
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Table 3. Changes in blood pressure, heart rate and P-wave parameters in the nebivolol and 
quinapril groups
SBP represent systolic blood pressure; DBP, diastolic blood pressure; Pmax, maximum P-wave; Pmin, minimum P-
wave; PWD, P-wave dispersion; ms, millisecond; mm, millimeter.
A 2 (Time) x 2 (Group) mixed-model repeated ANOVA revealed that the main effect of Time 
was still significant for Pmax (P=0.002) and PWD (P=0.008) after controlling for delta SBP, 
delta DBP and delta HR (Table 4). However, again, the main effect of Group and Time x Group 
interaction was not significant for both variables (All p values >0.05).
Table 4. Main effect of Time, Group and Time x Group interaction on P-wave parametres
Analysis was based on a 2 (Time) x 2 (Group) mixed-model repeated-measures analysis of variance. The results 
were adjusted for the changes in blood pressure and heart rate. Pmax represent maximum P-wave; Pmin, minimum 
P-wave; PWD, P-wave dispersion.
During the study period, cough occurred only in one patient in the quinapril group. In the 
nebivolol group, one patient experienced headache, and one patient experienced weakness. No 
other   clinical   side   effect   or   laboratory   abnormality   observed   during   the   study   period.
Discussion
To our knowledge, this is the first study to compare the effect of beta- blockers and ACE 
inhibitors on the P-wave duration and dispersion. We showed that nebivolol and quinapril 
treatment produce a similar but significant reduction in Pmax and PWD in patients with newly 
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diagnosed hypertension. Moreover, this effect was independent of blood pressure and heart rate 
changes.
Increased Pmax and PWD are believed to reflect heterogeneous and prolonged atrial conduction 
[1]. Independent of age, Pmax and PWD are predictors for the onset of AF in patients with 
hypertension [11]. Hypertension related changes in the left atrium including altered left atrial 
electrophysiology, increased left atrial pressure, stretch, dilatation and fibrosis are associated with 
development of AF [12,13]. Atrial electrophysiological changes can occur early in hypertension 
and may even precede left atrial enlargement [14]. Prolongation of atrial conduction times and 
shortening of the atrial effective refractory period (AERP) with loss of its rate dependence are the 
most characteristic features of atrial electrical remodeling [15]. Patients at very early stages of 
hypertension have demonstrable evidence of prolonged atrial conduction by P-wave signal-
averaged   ECG   [14].                                                                                    
The density of angiotensin (Ang)-II receptors in the atria is generally greater than in the ventricles 
[16] and Ang-II may contribute  directly to atrial electrical remodeling [13,17]. Experimentally, 
the inhibition of endogenous Ang-II with candesartan and captopril prevented AERP shortening 
during rapid atrial pacing in dogs [17]. Stimulation of Ang II type 1 receptors promotes fibroblast 
proliferation and collagen synthesis and thereby atrial fibrosis [13,18]. Atrial fibrosis may cause 
heterogeneity in atrial conduction and has been suggested to play a role in occurrence of AF 
[12,13]. Moreover, P-wave duration tends to increase as atrial ﬁbrosis increases [19]. ACE 
inhibitors reduce the Ang-II dependant activation of several intracellular signaling pathways 
mediating cell growth, proliferation, fibrosis and inflammation [13,18]. Thus, modification of 
atrial  electrical  and/or  structural   remodeling  with  quinapril  is  probably  one  of   the   main 
mechanisms for Pmax and PWD reduction observed in this study. Activation of the sympathetic 
nervous system may also contribute to prolongation and heterogeneity of atrial conduction 
[20,21]. RAS inhibition can modulate sympathetic nervous system activity [18]. Inflammation is 
increasingly recognized as a central feature in the pathogenesis of AF [22]. Thus, another potential 
mechanism in this setting may be associated with anti-inflammatory action of RAS inhibition 
[18,23]. Blocking the RAS can therefore offer an incremental benefit beyond its blood pressure 
lowering effect.  Consequently, a recent meta-analysis of 11 trials, revealed that RAS inhibition 
with ACE inhibitors or ARBs reduces incidence of AF in a wide range of diseases including 
hypertension, heart failure, myocardial infarction, and after electrical cardioversion [5].         
There are several possible direct or indirect mechanisms by which nebivolol might reduce the 
prolongation of the maximum duration and dispersion of the P-wave. Beta-blockers lengthen 
duration of diastole, enhance ventricular filling, decrease atrial pressure, and dilatation and thereby 
may improve stretch related arrhythmogenic mechanisms [11,24,25]. Increased sympathetic drive 
has been shown to induce atrial tachyarrhythmias [26] and beta blockers prevented AF recurrences 
in patients with hypertension [27,28]. Thus, another potential explanation may be the attenuation 
of the actions of the sympathetic nervous system on atrial electrical physiology. Hypertension may 
also induce atrial ischemia which further contributes to the heterogeneous and prolonged atrial 
conduction. Beta-blockers may reduce atrial ischaemia and fibrosis in those with underlying 
ischemic heart disease [29,30]. Nebivolol may promote nitric oxide (NO) bioactivity and 
vasodilatation   by   inhibiting   oxidative   stress   and   inflammation   [8].   Moreover,   nebivolol 
significantly reduced coronary artery smooth  muscle cell growth [31,32]. Combination of 
improved NO bioactivity, reduced oxidative stress, inflammation and inhibition of smooth muscle 
cell growth with nebivolol treatment may improve ischemia induced prolongation of atrial 
conduction. Consistent  with this data, beta-blockers  have  been shown  to be  effective in 
adrenergically mediated AF [33], in prevention of postoperative AF [34] and in reducing relapse 
rates of AF following cardioversion [28]. Recently, in a meta-analysis of 7 trials, including 11952 
heart failure patients, beta blockers significantly reduced incidence of AF [7].               
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 9 (3): 158-166 (2009)Hasan  Korkmaz, Orhan Onalan, Mehmet Akbulut, Yılmaz Ozbay,                         164 
“Nebivolol And Quinapril Reduce P-Wave Duration And Dispersion In Hypertensive Patients”
In conclusion, antihypertensive treatment with nebivolol and quinapril produces a similar but 
significant reduction in PWD and Pmax. Our results also suggest that reduction of Pmax and PWD 
cannot be solely attributed to a better blood pressure control since effect of both quinapril and 
nebivolol on Pmax and PWD was independent of blood pressure and heart rate changes. Further 
studies are required to assess clinical utility of Pmax and PWD reduction after the administration 
of anti-hypertensive treatment for the prevention of AF.                                                           
Several limitations should be considered. This study is subject to the limitations inherent to a 
nonrandomized study. A second limitation of the study is the small sample size. P-wave 
measurements were performed manually on the standard paper ECG. A digitized measurement 
method  for P-Wave parameters would be more accurate.                                             
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